The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

And when I look at KEYTRUDA back in 2019, internationally ... So really excited with sotatercept, WINREVAIR is its brand name. We received the approval. We're launching in Germany and Austria as we ...

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...

The company confirms Apple Intelligence will launch in October. 'Beetlejuice Beetlejuice' is a hit. 50 stocks that could see ...